Characterization of treatment patterns and outcomes in muscle-invasive bladder cancer patients in Sweden
DOI:
https://doi.org/10.2340/sju.v60.43875Keywords:
Bladder-intact event-free survival, bladder-sparing treatment, event-free survival, muscle-invasive bladder cancer, overall survival, radical cystectomyAbstract
Objective: For patients diagnosed with muscle-invasive bladder cancer (MIBC), prognosis remains poor with high rates of progression and risk for mortality. To better understand the current treatment landscape, this study aims to describe real-world treatment patterns and clinical outcomes for MIBC patients in Sweden.
Materials and methods: Using population-based registers and electronic medical records, patients with MIBC (T2-4aN0M0) were identified between January 2016 and December 2020 in the Skåne region in Sweden. Patients with de novo MIBC and those who progressed from high-risk nonmuscle-invasive bladder cancer were included. Treatment patterns, overall survival (OS), metastatic rate, event-free survival (EFS), and bladder-intact EFS (BI-EFS) were described.
Results: Among the 231 MIBC patients identified, 34% received only best supportive care (BSC) primarily due to age and comorbidity. Of the 153 patients who received curative treatment, 84 (55%) underwent radical cystectomy (RC) and 69 (45%) received bladder-sparing treatment. Patients who received bladder-sparing treatment were older, had poorer health status, and more comorbidities. Among RC-treated patients, 5-year OS and EFS were 74% (95% confidence interval [CI]: 61–83%) and 70% (95% CI: 58–79%), respectively. Among patients who received bladder-sparing treatment, 5-year OS and BI-EFS were 52% (95% CI: 38–64%) and 34% (95% CI: 21–48%), respectively.
Conclusions: Old age and high rates of comorbidities among the MIBC patient population meant many patients were ineligible for recommended RC and instead received bladder-sparing treatment or BSC only. High rates of progression and poor survival were observed in both patients undergoing RC and patients who received bladder-sparing treatment.
Downloads
References
752-sweden-fact-sheets.pdf. [cited 29-12-2023]. Available from: https://gco.iarc.fr/today/data/factsheets/populations/752-sweden-fact-sheets.pdf
Lobo N, Brooks NA, Zlotta AR, et al. 100 years of Bacillus Calmette–Guérin immunotherapy: from cattle to COVID-19. Nat Rev Urol. 2021;18(10):611–622. https://doi.org/10.1038/s41585-021-00481-1 DOI: https://doi.org/10.1038/s41585-021-00481-1
Burger M, Catto JWF, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234–241. https://doi.org/10.1016/j.eururo.2012.07.033 DOI: https://doi.org/10.1016/j.eururo.2012.07.033
Witjes JA, Bruins HM, Cathomas R, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: summary of the 2020 Guidelines. Eur Urol. 2021;79(1):82–104. https://doi.org/10.1016/j.eururo.2020.03.055 DOI: https://doi.org/10.1016/j.eururo.2020.03.055
Chang SS, Bochner BH, Chou R, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. J Urol. 2017;198(3):552–559. https://doi.org/10.1016/j.juro.2017.04.086 DOI: https://doi.org/10.1016/j.juro.2017.04.086
Maibom SL, Joensen UN, Poulsen AM, et al. Short-term morbidity and mortality following radical cystectomy: a systematic review. BMJ Open. 2021;11(4):e043266. https://doi.org/10.1136/bmjopen-2020-043266 DOI: https://doi.org/10.1136/bmjopen-2020-043266
Kimura T, Ishikawa H, Kojima T, et al. Bladder preservation therapy for muscle invasive bladder cancer: the past, present and future. Jpn J Clin Oncol. 2020;50(10):1097–1107. https://doi.org/10.1093/jjco/hyaa155 DOI: https://doi.org/10.1093/jjco/hyaa155
Nationellt vårdprogram cancer i urinblåsa, njurbäcken, urinledare och urinrör – RCC Kunskapsbanken. [cited 6-3-2024]. Available from:https://kunskapsbanken.cancercentrum.se/diagnoser/urinblase-och-urinvagscancer/vardprogram/
Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–655. DOI: https://doi.org/10.1097/00000421-198212000-00014
Carvalho FLF, Zeymo A, Egan J, et al. Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer. Investig Clin Urol. 2020;61(4):390–396. https://doi.org/10.4111/icu.2020.61.4.390 DOI: https://doi.org/10.4111/icu.2020.61.4.390
Cowan NG, Chen Y, Downs TM, et al. Neoadjuvant chemotherapy use in bladder cancer: a survey of current practice and opinions. Adv Urol. 2014;2014:746298. https://doi.org/10.1155/2014/746298 DOI: https://doi.org/10.1155/2014/746298
Schiffmann J, Sun M, Gandaglia G, et al. Use of adjuvant chemotherapy in radical cystectomy patients aged >65 years: a population-based study from the surveillance epidemiology and end results (SEER)-medicare database. Minerva Urol Nefrol. 2017;69(2):173–180. https://doi.org/10.23736/S0393-2249.16.02713-2 DOI: https://doi.org/10.23736/S0393-2249.16.02713-2
Körner SK, Jensen JB. A population-based retrospective analysis on variation in use of neoadjuvant chemotherapy depending on comorbidity in patients with muscle-invasive bladder cancer undergoing cystectomy in Denmark in the period 2013–2019. Scand J Urol. 2022;56(1):34–38. https://doi.org/10.1080/21681805.2021.2002400 DOI: https://doi.org/10.1080/21681805.2021.2002400
Eriksson V, Holmlund J, Wiberg E, et al. Adverse events during neoadjuvant chemotherapy for muscle invasive bladder cancer-a Swedish retrospective multicentre study of a clinical database. Transl Androl Urol. 2022;11(8):1105–1115. https://doi.org/10.21037/tau-22-78 DOI: https://doi.org/10.21037/tau-22-78
Jerlström T, Chen R, Liedberg F, et al. No increased risk of short-term complications after radical cystectomy for muscle-invasive bladder cancer among patients treated with preoperative chemotherapy: a nation-wide register-based study. World J Urol. 2020;38(2):381–388. https://doi.org/10.1007/s00345-019-02770-2 DOI: https://doi.org/10.1007/s00345-019-02770-2
Booth CM, Siemens DR, Li G, et al. Perioperative chemotherapy for muscle-invasive bladder cancer: a population-based outcomes study. Cancer. 2014;120(11):1630–1638. https://doi.org/10.1002/cncr.28510 DOI: https://doi.org/10.1002/cncr.28510
Sherif A, Holmberg L, Rintala E, et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol. 2004;45(3):297–303. https://doi.org/10.1016/j.eururo.2003.09.019 DOI: https://doi.org/10.1016/j.eururo.2003.09.019
Vlaming M, Kiemeney LALM, van der Heijden AG. Survival after radical cystectomy: progressive versus De novo muscle invasive bladder cancer. Cancer Treat Res Commun. 2020;25:100264. https://doi.org/10.1016/j.ctarc.2020.100264 DOI: https://doi.org/10.1016/j.ctarc.2020.100264
Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666–675. https://doi.org/10.1200/JCO.2001.19.3.666 DOI: https://doi.org/10.1200/JCO.2001.19.3.666
Häggström C, Garmo H, de Luna X, et al. Survival after radiotherapy versus radical cystectomy for primary muscle-invasive bladder cancer: a Swedish nationwide population-based cohort study. Cancer Med. 2019;8(5):2196–2204. https://doi.org/10.1002/cam4.2126 DOI: https://doi.org/10.1002/cam4.2126
Bochner BH, Dalbagni G, Sjoberg DD, et al. Comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: a randomized clinical trial. Eur Urol. 2015;67(6):1042–1050. https://doi.org/10.1016/j.eururo.2014.11.043 DOI: https://doi.org/10.1016/j.eururo.2014.11.043
Sabir EF, Holmäng S, Liedberg F, et al. Impact of hospital volume on local recurrence and distant metastasis in bladder cancer patients treated with radical cystectomy in Sweden. Scand J Urol. 2013;47(6):483–490. https://doi.org/10.3109/21681805.2013.787118 DOI: https://doi.org/10.3109/21681805.2013.787118
Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–866. https://doi.org/10.1056/NEJMoa022148 DOI: https://doi.org/10.1056/NEJMoa022148
Salminen AP, Koskinen I, Perez IM, et al. Neoadjuvant chemotherapy does not increase the morbidity of radical cystectomy: a 10-year retrospective nationwide study. Eur Urol Oncol. 2018;1(6):525–530. https://doi.org/10.1016/j.euo.2018.06.014 DOI: https://doi.org/10.1016/j.euo.2018.06.014
Russell B, Liedberg F, Khan MS, et al. A systematic review and meta-analysis of delay in radical cystectomy and the effect on survival in bladder cancer patients. Eur Urol Oncol. 2020;3(2):239–249. https://doi.org/10.1016/j.euo.2019.09.008 DOI: https://doi.org/10.1016/j.euo.2019.09.008
Szabados B, Rodriguez-Vida A, Durán I, et al. Toxicity and surgical complication rates of neoadjuvant atezolizumab in patients with muscle-invasive bladder cancer undergoing radical cystectomy: updated safety results from the ABACUS trial. Eur Urol Oncol. 2021;4(3):456–463. https://doi.org/10.1016/j.euo.2020.11.010 DOI: https://doi.org/10.1016/j.euo.2020.11.010
Szabados B, Kockx M, Assaf ZJ, et al. Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. Eur Urol. 2022;82(2):212–222. https://doi.org/10.1016/j.eururo.2022.04.013 DOI: https://doi.org/10.1016/j.eururo.2022.08.037
Iacovino ML, Miceli CC, De Felice M, et al. Novel therapeutic opportunities in neoadjuvant setting in urothelial cancers: a new horizon opened by molecular classification and immune checkpoint inhibitors. Int J Mol Sci. 2022;23(3):1133. https://doi.org/10.3390/ijms23031133 DOI: https://doi.org/10.3390/ijms23031133
de Ruiter BM, van de Kamp MW, van Steenbergen JPZ, et al. A multicenter retrospective cohort series of muscle-invasive bladder cancer patients treated with definitive concurrent chemoradiotherapy in daily practice. Eur Urol Open Sci. 2022;39:7–13. https://doi.org/10.1016/j.euros.2022.02.010 DOI: https://doi.org/10.1016/j.euros.2022.02.010
Huddart RA, Birtle A, Maynard L, et al. Clinical and patient-reported outcomes of SPARE – a randomised feasibility study of selective bladder preservation versus radical cystectomy. BJU Int. 2017;120(5):639–650. https://doi.org/10.1111/bju.13900 DOI: https://doi.org/10.1111/bju.13900
Fahmy O, Khairul-Asri MG, Schubert T, et al. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urol Oncol. 2018;36(2):43–53. https://doi.org/10.1016/j.urolonc.2017.10.002 DOI: https://doi.org/10.1016/j.urolonc.2017.10.002
Ploussard G, Daneshmand S, Efstathiou JA, et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol. 2014;66(1):120–137. https://doi.org/10.1016/j.eururo.2014.02.038 DOI: https://doi.org/10.1016/j.eururo.2014.02.038
Martini A, Sfakianos JP, Renström-Koskela L, et al. The natural history of untreated muscle-invasive bladder cancer. BJU Int. 2020;125(2):270–275. https://doi.org/10.1111/bju.14872 DOI: https://doi.org/10.1111/bju.14872
Häggström C, Hagberg O, Gårdmark T, et al. Cohort profile: Bladder Cancer Data Base Sweden (BladderBaSe) 2.0. BMJ Open. 2022;12(12):e064898. https://doi.org/10.1136/bmjopen-2022-064898 DOI: https://doi.org/10.1136/bmjopen-2022-064898
SNRUBC. [cited 29-10-2024]. Available from: https://statistik.incanet.se/Urinblasecancer/
Oedorf K, Skaaheim Haug E, Liedberg F, et al. Perioperative management of radical cystectomy in the Nordic countries. Scand J Urol. 2019;53(1):51–55. https://doi.org/10.1080/21681805.2019.1583686 DOI: https://doi.org/10.1080/21681805.2019.1583686
Wiberg E, Vega A, Eriksson V, et al. A validation study of cT-Categories in the Swedish National Urinary Bladder Cancer Register-Norrland University Hospital. J Pers Med. 2023;13(7):1163. https://doi.org/10.3390/jpm13071163 DOI: https://doi.org/10.3390/jpm13071163
Wedholm A, Wiberg E, Styrke J, et al. Validation of clinical T stages and of prognostic negative markers in patients with muscle invasive bladder cancer: data in the Swedish National Bladder Cancer Registry vs. data from a detailed research database. Transl Androl Urol. 2024;13(12):2757770–2752770. https://doi.org/10.21037/tau-24-454 DOI: https://doi.org/10.21037/tau-24-454
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Kelvin H.M. Kwok, Ahmad Abbadi, Sarah Côté, Simona Baculea, Samuel Spigelman, Markus Aly, Frida Schain
This work is licensed under a Creative Commons Attribution 4.0 International License.
As from Volume 59 (2024) all published articles, unless otherwise specified, are published under CC-BY license, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
